Recent research suggests that hypometabolism is evident in the frontal cortex of individuals with schizophrenia. Coenzyme-Q10 (Co-Q10), metabolic enhancer and potent free-radical scavenger, could effectively enhance metabolism in the brains of schizophrenics, thus improving their cognitive function and deficit symptoms. Research also suggests that free-radical scavengers such as coenzyme-Q-10 could be effective in the treatment of Tardive Dyskinesia. Subjects will undergo a double-blind, placebo-controlled, crossover trial of Co-Q10, as well as assessments with the BPAS, SANS, AIMS, and neuropsychological tests. We are still in the preliminary stages of the study. So far, seven patients have completed the study, and three are currently enrolled (n-10). Preliminary data show significant improvement in verbal recall for the seven patients who have completed the study. NMR 31-P-spectroscopy will assess brain activity levels while patients are taking Co-Q10.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH002596-03
Application #
3759482
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code